Pembrolizumab‐induced interstitial lung disease following thoracic surgery in a patient with non‐small cell lung cancer

The safety of treatment with immune‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Tetsuo, Hayama, Nami, Kuroki, Tsuguko, Shiraishi, Yuka, Amano, Hiroyuki, Nakamura, Makoto, Hirano, Satoshi, Aramaki, Nao, Ichinose, Shuji, Shimizu, Shinichiro, Tabeta, Hiroshi, Nakamura, Sukeyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825914/
https://www.ncbi.nlm.nih.gov/pubmed/31512401
http://dx.doi.org/10.1111/1759-7714.13194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825914/
https://www.ncbi.nlm.nih.gov/pubmed/31512401
http://dx.doi.org/10.1111/1759-7714.13194

Ejemplares similares